B A S E C A R E
Good news | Basecare Medical was honored in the "list of proposed projects of Suzhou 2022 intellectual property intensive product cultivation plan"
July 01,2022 · Suzhou
Recently, the evaluation results of Suzhou 2022 intellectual property plan project were announced, and the "intellectual property intensive product cultivation plan project of preimplantation genetic testing kit" of Basecare Medical was listed in the "list of proposed projects of Suzhou 2022 intellectual property intensive product cultivation plan".

Recently, the evaluation results of Suzhou2022 intellectual property plan project were announced, and the "intellectualproperty intensive product cultivation plan project of preimplantation genetictesting kit" of Basecare Medical was listed in the "list of proposedprojects of Suzhou 2022 intellectual property intensive product cultivationplan".

In October 2021, the State Council issuedthe national plan for the protection and application of intellectual propertyrights during the 14th Five Year Plan period, which proposed for the first timeto "cultivate patent intensive industries and explore the identificationof patent intensive products", so as to promote the integration ofintellectual property rights into industrial innovation and development. InJune, 2022, according to the requirements of the three-year action plan for thehigh-quality development of intellectual property in Suzhou (2021 ~ 2023), theaction plan for the peak of intellectual property in Suzhou enterprises (2021 ~2023), and other documents, after the review of the expert group, on-sitedefense, credit review, and the study and determination of the Bureau's Partygroup meeting, only 15 enterprises were finally selected into the list,including Basecare Medical.


The "preimplantation genetic testingkit intellectual property intensive product cultivation plan project"selected this time includes preimplantation genetic testing kit products andrelated instruments and equipment independently developed by Basecare Medical.Among them, PGT-A kit is the first three generation in vitro baby gene testingkit approved by NMPA. In addition, the company is developing twopreimplantation genetic testing (PGT) products, PGT-M kit and PGT-SR kit haveparticipated in the localization kit project of the national key R & Dproject of "reproductive health and women's and children's healthsecurity" in the 14th five year plan, and are expected to be registeredand approved by NMPA in 2023 and 2024 respectively.

Intellectual property intensive productsare a strong driving force for the integration of intellectual property intoindustrial innovation and development, and a key element to promote thehigh-quality development of the industry. Since its establishment, Basecare Medicalhas been aware of the importance of the creation, protection and application ofintellectual property rights, and has always attached great importance to themanagement of enterprise intellectual property rights. As of December 31, 2021,the company has obtained 53 patent authorizations and 117 registered trademarksin China. In 2021 alone, 35 new authorized patents have been obtained, and amanagement system in line with the national standard GB/T 29490-2013"norms for the management of intellectual property rights inenterprises" has been established, which has effectively improved themanagement and protection ability of the company's intellectual property rightsand enhanced the actual effectiveness of the transformation of property rightsachievements.

In May this year, Basecare Medical has beensuccessfully selected into the "list of the first batch of growingenterprises of Suzhou intellectual property strong enterprise cultivationproject", and this time it has been selected into the "list ofproposed projects of Suzhou 2022 intellectual property intensive productcultivation plan", which reflects the affirmation of Suzhou Municipalgovernment on the protection and application of Basecare Medical intellectualproperty and its high-quality development ability. In the future, Basecare Medicalwill continue to increase its R & D investment and produce more productswith R & D intensity and intellectual property intensity higher than theindustry average and in line with the national industrial developmentorientation through independent innovation, providing strong support for thecompany's excellent market competitiveness and the healthy and orderlydevelopment of the assisted reproductive industry.